...
首页> 外文期刊>Frontiers in Immunology >Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release
【24h】

Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release

机译:在大多数塔斯马尼亚恶魔准备野生释放的过程中,产生针对恶魔性面部肿瘤疾病的体液IgG免疫反应的免疫策略。

获取原文
           

摘要

Devil facial tumor disease (DFTD) is renowned for its successful evasion of the host immune system. Down regulation of the major histocompatabilty complex class I molecule (MHC-I) on the DFTD cells is a primary mechanism of immune escape. Immunization trials on captive Tasmanian devils have previously demonstrated that an immune response against DFTD can be induced, and that immune-mediated tumor regression can occur. However, these trials were limited by their small sample sizes. Here, we describe the results of two DFTD immunization trials on cohorts of devils prior to their wild release as part of the Tasmanian Government’s Wild Devil Recovery project. 95% of the devils developed anti-DFTD antibody responses. Given the relatively large sample sizes of the trials ( N ?=?19 and N ?=?33), these responses are likely to reflect those of the general devil population. DFTD cells manipulated to express MHC-I were used as the antigenic basis of the immunizations in both trials. Although the adjuvant composition and number of immunizations differed between trials, similar anti-DFTD antibody levels were obtained. The first trial comprised DFTD cells and the adjuvant combination of ISCOMATRIX?, polyIC, and CpG with up to four immunizations given at monthly intervals. This compared to the second trial whereby two immunizations comprising DFTD cells and the adjuvant combination ISCOMATRIX?, polyICLC (Hiltonol~(?)) and imiquimod were given a month apart, providing a shorter and, therefore, more practical protocol. Both trials incorporated a booster immunization given up to 5?months after the primary course. A key finding was that devils in the second trial responded more quickly and maintained their antibody levels for longer compared to devils in the first trial. The different adjuvant combination incorporating the RNAase resistant polyICLC and imiquimod used in the second trial is likely to be responsible. The seroconversion in the majority of devils in these anti-DFTD immunization trials was remarkable, especially as DFTD is hallmarked by its immune evasion mechanisms. Microsatellite analyzes of MHC revealed that some MHC-I microsatellites correlated to stronger immune responses. These trials signify the first step in the long-term objective of releasing devils with immunity to DFTD into the wild.
机译:魔鬼面部肿瘤病(DFTD)以成功逃避宿主免疫系统而闻名。 DFTD细胞上主要的组织相容性复杂的I类分子(MHC-1)的下调是免疫逃逸的主要机制。塔斯马尼亚圈养魔鬼的免疫试验先前证明,可以诱导针对DFTD的免疫反应,并且可以发生免疫介导的肿瘤消退。但是,这些试验由于样本量小而受到限制。在这里,我们描述了塔斯马尼亚政府实施的野生魔鬼恢复项目的一部分,在恶魔野外释放之前进行的两项DFTD免疫试验的结果。 95%的魔鬼产生了抗DFTD抗体反应。考虑到试验的样本量相对较大(N == 19和N = 33),这些反应可能反映了一般魔鬼的反应。在两个试验中,被操纵以表达MHC-1的DFTD细胞被用作免疫的抗原基础。尽管试验之间的佐剂组成和免疫次数不同,但获得了相似的抗-DFTD抗体水平。第一个试验包括DFTD细胞和ISCOMATRIX?,polyIC和CpG的佐剂组合,每月间隔最多进行四次免疫。这与第二项试验相比较,后者两次免疫包括DFTD细胞和佐剂组合ISCOMATRIX®,polyICLC(Hiltonol?(?))和咪喹莫特,间隔一个月,从而提供了一个更短,因此更实用的方案。两项试验均纳入了初次疗程后长达5个月的加强免疫。一个关键的发现是,与第一次试验中的恶魔相比,第二次试验中的恶魔反应更快,并保持了更长的抗体水平。第二项试验中使用的结合了RNA酶抗性polyICLC和咪喹莫特的佐剂可能不同。在这些抗DFTD免疫试验中,大多数恶魔的血清转换非常显着,尤其是因为DFTD的免疫逃逸机制为特征。 MHC的微卫星分析表明,某些MHC-1微卫星与更强的免疫反应相关。这些试验标志着将对DFTD具有免疫力的恶魔释放到野外的长期目标的第一步。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号